Jazz Receives FDA Approval For Ziihera Regimens In First-Line HER2+ Gastroesophageal Cancer

Jazz Pharmaceuticals announced FDA approval of two Ziihera (zanidatamab-hrii)-containing regimens for first-line treatment in adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal cancers. The regulatory greenlight expands the company’s labeled use for Ziihera and supports a positive near-term outlook for the franchise.